United Cannabis Corp - FORM 10-Q

Attached files

file	filename
EX-31 - CERTIFICATION - United Cannabis Corp	cnab_ex31z1.htm
EX-32 - CERTIFICATION - United Cannabis Corp	cnab_ex32z1.htm

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________________to__________________________

Commission File Number: 000-54582

United Cannabis Corporation

(Exact name of Registrant as specified in its charter)


Colorado		46-5221947
(State or other jurisdiction of incorporation or formation)		(I.R.S. employer identification number)

1600 Broadway, Suite 1600

Denver, Colorado 80202

(Address of principal executive offices)

(303) 386-7321

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

(Do not check if a smaller reporting company)

Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

On November 13, 2015, there were 44,988,500 shares of the issuer’s common stock outstanding.

UNITED CANNABIS CORPORATION

INDEX


		Page No.
PART I	FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS:
	Condensed Consolidated Balance Sheets — September 30, 2015 (Unaudited) and December 31, 2014	1
	Condensed Consolidated Statements of Operations (Unaudited) — Three and nine months ended September 30, 2015 and 2014	2
	Condensed Consolidated Statements of Cash Flows (Unaudited) — Nine months ended September 30, 2015 and 2014	3
	Notes to Condensed Consolidated Financial Statements (Unaudited) — Three and nine months ended September 30, 2015 and 2014	5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	20
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	25
ITEM 4.	CONTROLS AND PROCEDURES	26

PART II	OTHER INFORMATION

ITEM 1	LEGAL PROCEEDINGS	27
ITEM 1A	RISK FACTORS	27
ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	27
ITEM 3	DEFAULTS UPON SENIOR SECURITIES	27
ITEM 4	MINE SAFETY DISCLOSURES	27
ITEM 5	OTHER INFORMATION	28
ITEM 6	EXHIBITS	28
	SIGNATURES	29

PART 1. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

UNITED CANNABIS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	September 30, 2015			December 31, 2014

ASSETS
Current assets:
Cash and cash equivalents	$	2,671		$	321,353
Accounts receivable, net		17,227			6,245
Due from related parties		7,543			44,012
Prepaid expenses		72,224			177,400
Total current assets		99,665			549,010

Intangible assets		19,994			18,210
Investments in non-marketable equity securities		593,750			593,750
Equity method investments		88,000			138,000
Total assets	$	801,409		$	1,298,970

LIABILITIES & STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$	145,002		$	27,424
Due to related parties		16,981			—
Accrued expenses		628,101			550,795
Current portion of deferred revenue		380,000			500,000
Notes payable		775,000			775,000
Total current liabilities		1,945,084			1,853,219

Long term liabilities:
Deferred revenue, net of current portion		428,750			443,750
Total liabilities		2,373,834			2,296,969

Stockholders' deficit:
Preferred stock, no par value; 10,000,000 shares authorized; none issued and outstanding		—			—
Common stock, no par value; 100,000,000 shares authorized; 44,958,500 and 44,060,000 shares issued and outstanding, respectively		3,027,448			1,626,968
Accumulated deficit		(4,599,873	)		(2,624,967	)
Total stockholders' deficit		(1,572,425	)		(997,999	)
Total liabilities and stockholders' deficit	$	801,409		$	1,298,970

See accompanying notes to unaudited condensed consolidated financial statements.

UNITED CANNABIS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenues:
Revenues, non-affiliates	$	133,553		$	91,113		$	531,318		$	91,113
Revenues, affiliate		—			—			4,425			—
Total revenues		133,553			91,113			535,743			91,113
Cost of revenues:
Cost of revenues, non-affiliate		(22,652	)		(2,136	)		(129,670	)		(2,136	)
Cost of revenues, affiliate		(46,409	)		—			(46,409	)		—
Total cost of revenues		(69,061	)		(2,136	)		(176,079	)		(2,136	)
Gross profit		64,492			88,977			359,664			88,977

Operating expenses:
Sales and marketing		400			20,205			2,100			94,363
Research and development		—			94,751			329			170,805
General and administrative		361,794			522,421			1,412,243			946,562
Total operating expenses		362,194			637,377			1,414,672			1,211,730

Loss from operations		(297,702	)		(548,400	)		(1,055,008	)		(1,122,753	)

Other (income) expense:
Interest (income)		—			(13,154	)		—			(13,179	)
Interest and other expense		20,353			171,392			60,396			171,392
Equity in net loss of unconsolidated affiliate		—			—			90,900			—
Loss on settlement of disputed terms of warrant		—			—			768,602			—
Total other (income) expense		20,353			158,238			919,898			158,213

Loss from continuing operations		(318,055	)		(706,638	)		(1,974,906	)		(1,280,966	)

Net loss from discontinued operations		—			—			—			(58,892	)

Net loss	$	(318,055	)	$	(706,638	)	$	(1,974,906	)	$	(1,339,858	)

Basic and diluted net loss per share:
Continuing operations	$	(0.01	)	$	(0.02	)	$	(0.04	)	$	(0.03	)
Discontinued operations		n/a			n/a			n/a			(0.00	)	*
Net loss per share	$	(0.01	)	$	(0.02	)	$	(0.04	)	$	(0.03	)

Basic and diluted weighted-average common shares outstanding:		44,925,837			43,656,304			44,729,886			43,389,744

———————

Denotes loss of less than $0.01 per share.

See accompanying notes to unaudited condensed consolidated financial statements.

UNITED CANNABIS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine Months Ended September 30,
	2015			2014
Operating activities:
Net loss	$	(1,974,906	)	$	(1,339,858	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Bad debt expense		19,845			—
Loss on sale of assets of discontinued operations		—			15,704
Amortization of debt discount		—			89,152
Non-cash interest expense		—			11,609
Convertible note payable issued for debt issuance costs		—			32,500
Loss on origination of derivative liability		—			12,810
Loss on revaluation of derivative liability		—			1,942
Share-based compensation expense		642,109			34,000
Value of non-marketable equity securities recognized as revenue		(135,000	)		(75,000	)
Equity in net loss of unconsolidated affiliate		90,900			—
Loss on settlement of disputed terms of warrant		768,602			—
Changes in operating assets and liabilities:
Accounts receivable		(27,715	)		(16,113	)
Interest receivable		—			(13,150	)
Due from related party		(7,543	)		10,774
Due to related party		16,981			—
Prepaid expenses		(7,718	)		(26,450	)
Accounts payable and accrued expenses		310,148			169,023
Net cash provided by (used in) operating activities		(304,297	)		(1,093,057	)

Investing activities:
Equity method investments		—			(50,000	)
Purchase of intangible assets		(14,385	)		—
Net cash provided by (used in) investing activities		(14,385	)		(50,000	)

Financing activities:
Net proceeds from issuance of convertible debt and warrants		—			225,000
Proceeds from issuance of note payable		—			175,000
Proceeds from issuance of common shares and warrants		—			900,000
Net cash provided by (used in) financing activities		—			1,300,000

Net increase (decrease) in cash		(318,682	)		156,943

Cash, beginning of period		321,353			32,414

Cash, end of period	$	2,671		$	189,357

See accompanying notes to unaudited condensed consolidated financial statements.

UNITED CANNABIS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine Months Ended September 30,
	2015			2014
Supplemental schedule of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for income taxes	$	—		$	—

Supplemental disclosure of non-cash investing and financing activities:
Cancellation of warrant	$	(218,788	)	$	—
Issuance of common stock for repurchase of warrant and in settlement of disputed terms of warrant	$	987,390		$	—
Issuance of common stock for services	$	214,215		$	162,000
Issuance of stock options	$	417,664		$	—
Investment in non-marketable equity securities for deferred services	$	—		$	893,750
Investment in equity method investments received for common stock	$	—		$	88,000
Acquisition of notes receivable funded by convertible note payable	$	—		$	1,250,000
Issuance of convertible note payable for debt issuance costs	$	—		$	32,500
Warrants issued for debt discount	$	—		$	694,525
Debt conversion feature issued for debt discount	$	—		$	151,937
Conversion of note payable, related party, into common stock	$	—		$	50,000

See accompanying notes to unaudited condensed consolidated financial statements.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS

On March 19, 2014, we effected a four-for-one stock split of our outstanding shares of common stock. All references to shares of our common stock in our condensed consolidated financial statements refer to the number of shares of common stock after giving effect to the stock split (unless otherwise indicated).

Background and Current Operations

United Cannabis Corporation ("we", "our", "us", "UCANN", or “our Company”), a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold.

In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and licensing intellectual property to the cannabis industry.

On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.

In connection with this transaction:


·	Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry.

·	The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement.

·	Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014.

·	Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President.

·	A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014.

UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation.

On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.

Government Regulation - Marijuana is a Schedule-I controlled substance and is illegal under federal law. Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal laws.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

As of September 30, 2015, 23 states and the District of Columbia allow their citizens to use medical marijuana, and four states and the District of Columbia have legalized marijuana for recreational use. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational marijuana. However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to us.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation - We prepared these condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2014. Operating results for the interim periods presented are not necessarily indicative of the results for the full year.

Principles of Consolidation – Our condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries UC Nevada L.L.C., UC Colorado Corporation and UCANN California Corporation. All intercompany accounts and transactions have been eliminated.

Use of Estimates - The preparation of our condensed consolidated financial statements in conformity with GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of our condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented.

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our condensed consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.

Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of our notes payable at September 30, 2015, approximates their fair values based on our incremental borrowing rates.

Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of September 30, 2015 and December 31, 2014.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer’s financial condition and credit history, and current economic conditions. We did not have an allowance for doubtful accounts as of September 30, 2015 and December 31, 2014 as we believe our accounts receivables are fully realizable as of those dates. We recorded bad debt expense, included in general and administrative expenses, of $3,220 and $19,845 during the three and nine months ended September 30, 2015, respectively. We did not record bad debt expense during the three and nine months ended September 30, 2014.

Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.

Prepaid Expenses - Prepaid expenses are primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods which approximate the life of the contract or service period.

Property and Equipment – Our property and equipment are recorded at cost. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over an estimated useful life of three to five years. Assets acquired under capital leases are depreciated over the lesser of the useful life of the asset or the lease term. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from our accounts and any resulting gain or loss is reflected in our condensed consolidated statements of operations.

Intangible Assets – Our intangible assets, consisting of trademarks, design mark and provisional patent applications are recorded at cost, and once approved, are amortized using the straight-line method over an estimated useful life of 10 to 20 years.

Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, if any. Impairments are based on methodologies, including the valuation achieved in the most recent private placement by the investee, an assessment of the impact of industry and general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other noncurrent assets.

Long-Lived Assets – Our intangible assets and other long-lived assets are subject to an impairment test if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, intangible assets and other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying value of intangibles or other long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, we use the projected undiscounted cash flow method to determine whether an impairment exists, and then measure the impairment using discounted cash flows.

We have not recorded any impairment charges related to long-lived assets as of September 30, 2015 or December 31, 2014.

Equity Method Investments – Our investments in entities representing ownership of at least 20% but not more than 50%, where we exercise significant influence, are accounted for under the equity method.

Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Revenue for services with a payment in form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid for with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred and collectability is reasonably assured. Generally, our suppliers drop-ship orders to our clients with origin terms. For any shipments with destination terms, we defer revenue until delivery is made to the customer. During 2014 and during the nine months ended September 30, 2015, sales returns were not significant and as such, no sales return allowance had been recorded as of September 30, 2015 and December 31, 2014.

Reimbursable expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses are included in total direct client service costs. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are presented in our condensed consolidated statement of operations on a net basis.

Cost of Revenues – Our policy is to recognize cost of revenues in the same manner as, and in conjunction with, revenue recognition. Our cost of revenues includes the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our Prana medicinals products and personnel-related costs, fees for third-party services, travel and other consulting costs related to our advisory services.

Shipping and Handling Costs - For product sales, shipping and handling costs are included as a component of cost of revenues. During the three and nine months ended September 30, 2015, we incurred shipping and handling costs of $0 and $1,013, respectively. We did not incur shipping and handling costs during the nine months ended September 30, 2014.

Advertising Costs - All advertising costs are expensed as incurred. During the three and nine months ended September 30, 2015 we incurred $0 and $1,500 of advertising costs, respectively. We did not incur advertising costs during the nine months ended September 30, 2014.

Research and Development Expenses - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

Sales and Marketing Expenses – Sales and marketing expenses consist primarily of fees for professional and consulting services, promotional events and advertising costs.

General and Administrative Expenses - General and administrative expenses consist primarily of personnel-related costs, fees for professional and consulting services, travel costs, rent, bad debt expense, general corporate costs, and other costs of administration such as human resources, finance and administrative roles.

Share-Based Compensation - We periodically issue shares of our common stock to non-employees in non-capital raising transactions for fees and services. We account for stock issued to non-employees in accordance with ASC 505, Equity, whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation, whereas the award is measured at its fair value at the date of grant and is amortized ratably over the vesting period. Accounting for share-based compensation to employees requires the measurement and recognition of compensation expense for all share-based payment awards made to employees based on estimated fair values. We estimate the fair value of all stock option awards on the date of grant using the Black-Scholes-Merton pricing model, which is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, actual and projected employee option exercise behaviors, risk free interest rates and expected dividends. We also estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates.

Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders’ deficit.

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our condensed consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying condensed consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our condensed consolidated statements of operations.

Commitments and Contingencies - Certain conditions may exist as of the date our condensed consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

Net Loss Per Share - We compute net loss per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net loss per share includes no dilution and is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic net loss per share) and potentially dilutive securities that are not anti-dilutive.

Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Warrants to purchase common stock		3,000,000		3,997,692		3,000,000		3,997,692
Stock options		600,000		—		600,000		—
Total potentially dilutive securities		3,600,000		3,997,692		3,600,000		3,997,692

Other Comprehensive Income (Loss) – We report as other comprehensive income (loss) those revenues, gains and losses not included in the determination of net income. During the three and nine months ended September 30, 2015 and 2014, we did not have any gains and losses resulting from activities or transactions that resulted in other comprehensive income or loss.

Segment Reporting – Our Company operates as one segment.

Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.

The following tables show significant concentrations in our revenues and accounts receivable (net of allowances for doubtful accounts) for the periods indicated:

Percentage of Revenue:


	Three Months Ended September 30,
	2015			2014
Customer A		35	%		—	%
Customer B		34	%		82	%
Customer C		31	%		—	%
Customer E		—	%		10	%


	Nine Months Ended September 30,
	2015			2014
Customer A		9	%		—	%
Customer B		25	%		82	%
Customer C		19	%		—	%
Customer D		37	%		—	%
Customer E		1	%		10	%

Percentage of Accounts Receivable:


	September 30, 2015			December 31, 2014
Customer A		96	%		—	%
Customer E		—			33	%
Customer F		—			46	%
Customer G		4	%		21	%

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our condensed consolidated financial statements upon adoption.

In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for us at the beginning of fiscal year 2018, and early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our condensed consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting.

NOTE 3 – GOING CONCERN

Our condensed consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2015, we incurred losses of $1,974,906 and used cash of $304,297 in our operating activities. As at September 30, 2015, we had a working capital deficit of $1,845,419 and an accumulated deficit of $4,599,873. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

NOTE 4 – INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES

On September 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD RX Inc. (“WMD”), a private Canadian company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The shares represented a 4.29% equity investment in WMD at the time of the investment and we do not have significant influence over the investee. We recorded our investment in these non-marketable equity securities at estimated cost.

The WMD common shares were recorded at $0.50 per share based on WMD’s most recent sale of their common shares prior to the date of the transaction (CAD $0.50). The $593,750 cost assigned is classified as investment in non-marketable equity securities on our condensed consolidated balance sheets.

On December 9, 2014, the 3,000,000 WMD warrants expired unexercised and we recorded a $300,000 loss on investment in non-marketable equity securities in our condensed consolidated statements of operations.

NOTE 5 – PREPAID EXPENSES

Prepaid expenses consist of:


	September 30, 2015		December 31, 2014
Prepaid corporate finance services	$	20,822	$	—
Prepaid investor relations services		4,167		121,500
Other prepaid services and fees		47,235		55,900
	$	72,224	$	177,400

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

NOTE 6 – EQUITY METHOD INVESTMENTS

Our equity method investments consist of:


	September 30, 2015		December 31, 2014
Lone Mountain Partners, LLC (“Lone Mountain”) – 25% interest	$	—	$	50,000
Cannabinoid Research & Development Company Limited (“CRD”) – 50% interest		88,000		88,000
Total equity method investments	$	88,000	$	138,000

Lone Mountain

On August 14, 2014, we acquired a 25% membership interest in Lone Mountain Partners, LLC, (“Lone Mountain”) for $50,000 and a commitment to provide future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Nevada and to provide standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of Lone Mountain. During the second half of 2014, we advanced Lone Mountain $40,900 for license application fees. As of December 31, 2014, Lone Mountain did not have any operations or operating activities. We accounted for our $50,000 cash contribution as an equity method investment and the $40,900 advance as amounts due from related parties on our condensed consolidated balance sheets.

During the first half of 2015, Lone Mountain incurred operating losses in excess of $400,000. We recognized our 25% share of these losses up to the carrying amount of our equity method investment and advances to Lone Mountain and included this total $90,900 loss in equity in net loss of unconsolidated affiliate in our condensed consolidated statements of operations.

We entered into a settlement agreement effective July 16, 2015, as amended on September 9, 2015, whereby we transferred our 25% equity interest in LMP to one of the LMP members in exchange for a mutual release from all claims against us, LMP and the other LMP members. This transaction did not impact our third quarter 2015 condensed consolidated financial statements as we have previously written off our investment in and advances to LMP.

CRD

On August 15, 2014, we acquired a 50% interest in Cannabinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange for 40,000 shares of our common stock valued at $88,000 based on the previous day’s closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as use of our intellectual property in the operations of CRD. As of September 30, 2015, CRD did not have any operations or operating activities. We accounted for this $88,000 as an equity method investment on our condensed consolidated balance sheets.

NOTE 7 – ACCRUED EXPENSES

Our accrued expenses consist of:


	September 30, 2015		December 31, 2014
Accrued consulting fees	$	110,000	$	110,000
Accrued wages and related costs		450,873		433,963
Accrued interest expense		67,228		6,832
Total accrued expenses	$	628,101	$	550,795

The $110,000 accrued consulting fees at September 30, 2015 and December 31, 2014, represent fees owed to consultants working on a research and development project that is approximately 80% complete. See also Note 12.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

NOTE 8 – DEFERRED REVENUE

Our deferred revenue consists of:


	September 30, 2015			December 31, 2014
Deferred revenue – WeedMD	$	608,750		$	743,750
Deferred revenue - FoxBarry		200,000			200,000
		808,750			943,750
Less – current portion		(380,000	)		(500,000	)
Deferred revenue, net of current portion	$	428,750		$	443,750

As described in Note 4 above, on September 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three year estimate of the service period involved. Based on recent discussions with WMD, we now expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four year period January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month and during the three and nine month periods ending September 30, 2015, we recognized a total of $45,000 and $135,000, respectively, of revenue applicable to this arrangement. At September 30, 2015, we expect to recognize $180,000 of the remaining $608,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $180,000 as a current liability on our condensed consolidated balance sheets.

On December 28, 2014, we entered into a royalty and consulting services agreement with FoxBarry Farms, LLC (“FoxBarry”) whereby we received a $200,000 prepaid royalty payment from FoxBarry. At the time we planned to recognize deferred royalty revenue based on actual applicable sales as defined in the agreement. During the three and nine months ended September 30, 2015, we did not recognize any deferred revenue related to this agreement. In August 2015 we discontinued providing consulting services to FoxBarry as our initial project with FoxBarry was abandoned due to operational issues. At the same time we entered into discussions with FoxBarry to earn the $200,000 prepaid royalty through new projects or as a potential termination fee associated with our original agreement. We have classified the $200,000 as a current liability on our condensed consolidated balance sheets as we expect to recognize this amount during the next twelve months.

NOTE 9 – NOTES PAYABLE

Our notes payable consist of:


	September 30, 2015		December 31, 2014
Note payable - WeedMD	$	175,000	$	175,000
Note payable – unrelated third party		600,000		600,000
Total notes payable	$	775,000	$	775,000

On July 7, 2014, we issued a $175,000, unsecured demand promissory note bearing interest at 5% to WeedMD for cash used in our business development activities. Interest expense during the three and nine months ended September 30, 2015, applicable to this note was $2,205 and $6,544, respectively, and accrued interest payable at September 30, 2015 and December 31, 21014, was $10,812 and 4,267, respectively.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

On December 18, 2014, we issued a $600,000 unsecured promissory note bearing interest at 12% to an unrelated third party. The principal and accrued interest are due on the earlier of December 17, 2015, or upon the closing of certain capital raising transactions as described in the note. The default rate of interest under the note is 18%. Debt issuance costs of $13,500 were immediately recognized as interest expense as, at the time, we expected to close on a capital raising transaction in early 2015. Interest expense during the three and nine months ended September 30, 2015, applicable to this note was $18,148 and $53,852, respectively, and accrued interest payable at September 30, 2015 and December 31, 2014, was $56,416 and $2,565, respectively.

NOTE 10 – STOCKHOLDERS’ DEFICIT

Stock Options

On January 9, 2015, we awarded 200,000 stock options to each of Messrs. Blackmon, Verzura and Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.70 per share during the ten year term of the option.

We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation:


Stock price	$	0.70
Exercise price	$	0.70
Risk free interest rate		1.98	%
Expected term (years)		10.0
Expected volatility		173	%
Expected dividends		0	%

At December 31, 2014, the fair value of these 600,000 options totaling $417,664 was included in accrued expenses on our condensed consolidated balance sheets and on January 9, 2015, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of the 600,000 options on that date.

The following table summarizes our stock options outstanding as of September 30, 2015 and December 31, 2014:


	Nine Months Ended September 30, 2015
	Number of Shares		Weighted Average Remaining Life (years)		Weighted Average Exercise Price
Stock options outstanding, beginning of period		—		—	$	—
Issued		600,000		10.0		0.70
Exercised		—		—		—
Expired		—		—		—
Stock options outstanding, end of period		600,000		9.3	$	0.70
Stock options exercisable, September 30, 2015		600,000		9.3	$	0.70

Common Stock Issued For Warrant Outstanding

On February 10, 2015, we issued 621,000 shares of our common stock valued at $987,390 based on the previous day’s closing price, to Typenex Co-Investment, LLC ("Typenex") in exchange for the return of Warrant #1 to Purchase Shares of Common Stock (the “Warrant”) that we issued to Typenex on August 13, 2014, as part of a financing arrangement.

On February 10, 2015, we calculated the fair value of the Warrant to be $218,788, or approximately $1.29 per underlying share, utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation:


Stock price	$	1.59
Exercise price	$	3.00
Risk free interest rate		1.05	%
Expected term (years)		2.6
Expected volatility		183	%
Expected dividends		0	%

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

The Warrant gave Typenex the right to purchase 170,044 shares of our common stock on the issuance date and provided for adjustments to the number of shares underlying the Warrant upon occurrence of certain events including subsequent sales of our common stock. Our repurchase of the Warrant resulted in Typenex forgoing its potential right to receive shares in excess of the original 170,044 shares underlying the Warrant on the original issuance date. On February 10, 2015, we recorded the $987,390 fair value of the common shares issued as an increase to common stock and the $218,788 fair value of the Warrant reacquired as a decrease to common stock and the difference, $768,602, as a loss on settlement of disputed terms of warrant in our condensed consolidated statements of operations.

Common Stock Issued For Services

On March 2, 2015, we issued 30,000 shares of common stock valued at $42,600, based on the previous trading day’s closing price, as consideration for consulting services from an independent contractor. The $42,600 of share-based compensation expense is included in included in general and administrative expense in our condensed consolidated statements of operations.

On April 23, 2015 we issued 60,000 shares of common stock valued at $47,400, based on the previous trading day’s closing price, as consideration for prepaid accounting fees. The $47,400 was recognized as share-based compensation expense as services were rendered. During the three and nine months ended September 30, 2015, we recorded $6,044 and $47,400, respectively, of share-based compensation expense and included these amounts in general and administrative expenses in our condensed consolidated statements of operations.

On April 23, 2015, we issued 126,500 shares of common stock valued at $99,935, based on the previous trading day’s closing price, as consideration for prepaid corporate finance fees. The $99,935 is being recognized as share-based compensation expense as services are rendered. During the three and nine months ended September 30, 2015, we recorded $49,967 and $83,279, respectively, of share-based compensation expense and included these amounts in general and administrative expenses in our condensed consolidated statements of operations. The remaining $16,656 as at September 30, 2015, is included in prepaid expenses on our condensed consolidated balance sheets and will be amortized on a straight-line basis over the one month remaining term of the contracts.

On August 17, 2015 we issued 50,000 shares of common stock valued at $19,000, based on the previous trading day’s closing price, as consideration for prepaid accounting fees. The $19,000 is being recognized as share-based compensation expense as services are rendered. During the three and nine months ended September 30, 2015, we recognized $13,471 of share-based compensation expense and included this amount in general and administrative expenses in our condensed consolidated statements of operations. The remaining $5,529 as at September 30, 2015, is included in prepaid expenses on our condensed consolidated balance sheets and will be recognized in the fourth quarter of 2015.

On August 24, 2015, we issued a total of 11,000 shares of common stock valued at $5,280, based on the previous trading day’s closing price, as consideration for consulting services from two independent contractors. The $5,280 of share-based compensation expense is included in included in general and administrative expense in our condensed consolidated statements of operations.

Warrants:

The following table summarizes our share warrants outstanding as of September 30, 2015 and December 31, 2014:


	Nine Months Ended September 30, 2015
	Number of Shares			Weighted Average Remaining Life (years)		Weighted Average Exercise Price
Warrants outstanding, beginning of period		3,170,044			1.3	$	11.52
Issued		—			—		—
Exercised		—			—		—
Repurchased and cancelled		(170,044	)		2.5		3.00
Expired		—			—		—
Warrants outstanding, end of period		3,000,000			0.5	$	12.00
Warrants exercisable, September 30, 2015		3,000,000			0.5	$	12.00

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

NOTE 11 – SHARE-BASED COMPENSATION

Share-based Compensation

We recognize share-based compensation expense in cost of revenues and general and administrative expense based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during 2015 under our 2014 Equity Incentive Plan. Share-based compensation expense for the three and nine months ended September 30, 2015 and 2014 is as follows:


	Three Months Ended September 30,
	2015		2014
Share-based compensation expense – shares issued for services	$	5,280	$	34,000
Share-based compensation expense – amortization of shares issued for prepaid services		70,482		—
Share-based compensation expense – accrual of estimated share-based awards		105,000		—
	$	180,762	$	34,000


	Nine Months Ended September 30,
	2015		2014
Share-based compensation expense – shares issued for services	$	47,880	$	34,000
Share-based compensation expense – amortization of shares issued for prepaid services		279,229		—
Share-based compensation expense – accrual of estimated share-based awards		315,000		—
	$	642,109	$	34,000

NOTE 12 –COMMITMENTS AND CONTINGENCIES

Contractual Obligations and Commercial Commitments

On May 6, 2014, we entered into a consultancy agreement with two third party consultants that has a nine month term which can be renewed and/or extended by mutual agreement; currently, the renewal of the agreement is under negotiations. The agreement provides for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments (a total of $200,000) and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement. During the three and nine months ended September 30, 2015, we did not recognize any expense applicable to this agreement. During the three and nine months ended September 30, 2014, we recognized $100,000 and $150,000, respectively, of expense applicable to this agreement and this amount is included in R&D expenses in our condensed consolidated statements of operations. At December 31, 2014, the project was approximately 80% complete. We then accrued $10,000 to R&D expense, thereby recognizing a total of $160,000 or 80% of the project costs. At September 30, 2015 and December 31, 2014, $110,000 is included in accrued expenses on our condensed consolidated balance sheets. The value of the 100,000 shares will be recognized upon achievement of the goals, currently anticipated to be during 2015. The progress has been suspended and it is unknown when it will resume.

Legal Proceedings

We are involved in disputes and legal actions arising in the normal course of our business. There have been no material developments in legal proceedings in which we are involved during the three and nine months ended September 30, 2015.

NOTE 13 –RELATED PARTY TRANSACTIONS

Affiliate Customer

During 2010 Messrs. Blackmon and Verzura have made loans to, or equity investments in, one of our customers and, effective June 30, 2015, Messrs. Blackmon and Verzura had completely divested themselves of those interests. As Messrs. Blackmon and Verzura may have had significant influence on management or operating polices of the customer until June 30, 2015, we have classified sales to this customer as revenues, affiliate, in our condensed consolidated statements of operations and accounts receivable from this customer as due from related parties on our condensed consolidated balance sheets.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

Lone Mountain

During the year ended December 31, 2014, we made certain payments on behalf of Lone Mountain during the organizational phase of this venture and we classified these payments as due from related parties on our condensed consolidated balance sheets. As further described in Note 6 above, during the first half of 2015, we expensed our $40,900 advance to Lone Mountain and included this amount in equity in net loss of unconsolidated affiliate in our condensed consolidated statements of operations.

CRD

On April 20, 2015, we advanced CRD $5,000 and included this amount in due from related parties.

Blue River Inc.

In February 2015 Messrs. Blackmon, Verzura and Ruby formed Blue River Inc. (“Blue River”), a Colorado corporation in the cannabis industry that plans to manufacture and wholesale medicinal and recreational cannabis products including our Prana medicinals products. During the three and nine months ended September 30, 2015, we advanced Blue River $2,543 and included this amount in due from related parties.

MedCor Staffing, Inc.

During the third quarter of 2015 Messrs. Blackmon, Verzura and Ruby acquired equity positions totaling 45%, in the aggregate, in MedCor Staffing, Inc. (“MedCor”) a New York corporation engaged in the healthcare staffing services industry. As Messrs. Blackmon, Verzura and Ruby may have had significant influence on management or operating polices of the supplier, we have classified purchases from this supplier as cost of revenues, affiliate, in our condensed consolidated statements of operations and we have classified accounts payable to this supplier as due to related parties on our condensed consolidated balance sheets. During the three and nine months ended September 30, 2015, we purchased $46,409 of services from MedCor and included this amount in cost of revenues, affiliate in our condensed consolidated statements of operations. At September 30, 2015, we owed MedCor $10,981in trade payables and included this amount in due to related parties.

Amounts due from related parties consist of:


	September 30, 2015		December 31, 2014
Affiliated customer	$	—	$	3,112
Lone Mountain		—		40,900
Blue River		2,543		—
CRD		5,000		—
Total due from related parties	$	7,543	$	44,012

Amounts due to related parties consist of:


	September 30, 2015		December 31, 2014
MedCor	$	10,981	$	—
Mr. Blackmon		4,000		—
Mr. Verzura		2,000		—
Total due from related parties	$	16,981	$	—

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

NOTE 14 –DISCONTINUED OPERATIONS

On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. See Note 1 for further detail on our change in operations.

The following details our loss from discontinued operations:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014

Revenues	$	—	$	—	$	—	$	20,684

Operating expenses:
Selling, general and administrative		—		—		—		63,872
Loss on disposal of assets		—		—		—		15,704
Total operating expenses		—		—		—		79,576

Loss from discontinued operations, before income taxes		—		—		—		(58,892	)
Provision for income taxes		—		—		—		—

Loss from discontinued operations, net of income taxes	$	—	$	—	$	—	$	(58,892	)

NOTE 15 – SUBSEQUENT EVENTS

On October 6, 2015 we borrowed $59,000 from Vis Vires Group, Inc. (the “Lender”), a New York corporation and issued an 8% unsecured convertible note (the “Vis Vires Note”) that has a maturity date of June 30, 2016. The Vis Vires Note and accrued interest is convertible, at any time after 180 days, into shares of our common stock at a price per share equal to 58% of the average of the three lowest closing bid prices for the 10 prior trading days ending on the latest complete trading day prior to the conversion date.

The terms of the Note limit the number of shares of our common stock into which the Vis Vires Note may be converted such that upon conversion, the Lender and its affiliates may not hold beneficially more than 9.99% of our outstanding common stock. Any amount of the principal or interest on the Vis Vires Note that is not paid when due bears interest at the rate of 22% per annum.

The Vis Vires Note contains customary covenants and provides for customary events of default.

As a result of the aforementioned borrowing, we are in technical default of certain covenants contained in our $600,000 unsecured promissory note which was originally due on December 17, 2015.

On October 8, 2015, we executed a 12% Convertible Note payable to JSJ Investments, Inc. (“JSJ”) in the principal amount of $102,000 (the “JSJ Note”), convertible into shares of our common stock upon the terms and subject to the limitations and conditions set forth in the JSJ Note. The JSJ Note was funded on October 12, 2015 and we received $93,900 after payment of legal and due diligence fees.

The JSJ Note, which has a maturity date of July 8, 2016, bears interest at the rate of 12% per annum, and, in the event of a default, the interest rate increases to 18%. Pursuant to the terms of the JSJ Note, JSJ is entitled, at its option, at any time after 180 days, to convert all or any part of the outstanding and unpaid principal and accrued interest into shares of our common stock at a price per share equal to a 45% discount to the average of the five lowest trading prices during the previous 10 trading days to the date of the conversion notice.

UNITED CANNABIS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2015 and 2014

(Unaudited)

The terms of the JSJ Note limit the number of shares of our common stock into which the JSJ Note may be converted such that upon conversion, JSJ and its affiliates may not hold beneficially more than 4.99% of our outstanding common stock.

The JSJ Note contains customary covenants and provides for customary events of default, and it contains certain prepayment provisions.

On October 19, 2015, we issued 30,000 shares of common stock valued at $12,000 based on the previous trading day’s closing price as consideration for prepaid intellectual property license fees.

In accordance with ASC 855-10 we have analyzed our operations subsequent to September 30, 2015, to the date these condensed consolidated financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these condensed consolidated financial statements.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion will assist in the understanding of our financial position and results of operations. The information below should be read in conjunction with our condensed financial statements, the related notes to our condensed consolidated financial statements and our Annual Report on Form 10-K for the year ended December 31, 2014.

In addition to historical information, this discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 regarding our expectations concerning our future operations, earnings and prospects. On the date the forward-looking statements are made, the statements represent our current expectations, but the expectations concerning our future operations, earnings and prospects may change. Our expectations involve risks and uncertainties (both favorable and unfavorable) and are based on many assumptions that we believe to be reasonable, but such assumptions may ultimately prove to be inaccurate or incomplete, in whole or in part. Accordingly, there can be no assurances that our expectations and the forward-looking statements will be correct. Please refer to our most recent Annual Report on Form 10-K for a description of risk factors that could cause actual results to differ (favorably or unfavorably) from the expectations stated in this discussion. We disclaim any obligation to update any of these forward-looking statements except as required by law.

Overview

United Cannabis Corporation ("we", "our", "us", "UCANN", or “our Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold.

In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry.

We own distinct intellectual property relating to the legalized growth, production, manufacture, marketing, management, utilization and distribution of medical and recreational marijuana and marijuana infused products. In our first two years of operating in the cannabis industry we have entered into agreements with partners outside of Colorado where we have agreed to provide intellectual property and consulting services and in which we have received an equity interest. These businesses are located in Jamaica and Canada. We have formalized strategic relationships with several other businesses located in Colorado and California in the cannabis industry and we provide consulting services, product placement services and licenses to our intellectual property in exchange for consulting and licensing fees. We also market and sell proprietary non-cannabis products used in the manufacture of our proprietary Prana medicinals products.

We plan to advance the use of cannabinoids in medicine through research, product development and education. We are dedicated to improving the lives of patients through the creation of products using only the highest quality genetics, purest extractions and most effective protocols possible. Our ACT Now Program and patent-pending Prana Bio Nutrient Medicinals provide a comprehensive solution, designed to enable physicians and patients to design, implement and monitor effective cannabinoid therapy protocols.

Results of Operations

Three Months Ended September 30, 2015 Compared to the Three Months Ended September 30, 2014

Revenues, Cost of Revenues and Gross Profits

Components of revenues, cost of revenues and gross profit consist of:


	Three Months Ended September 30, 2015
	Revenues		Cost of Revenues		Gross Profits
Non-cannabis products	$	—	$	—	$	—
License fees		55,262		1,000		54,262
Consulting fees		38,000		27,770		10,230
Reimbursable expenses		40,291		40,291		—
Total	$	133,553	$	69,061	$	64,492


	Three Months Ended September 30, 2014
	Revenues		Cost of Revenues		Gross Profits
Non-cannabis products	$	9,212	$	2,136	$	7,076
License fees		81,901		—		81,901
Consulting fees		—		—		—
Reimbursable expenses		—		—		—
Total	$	91,113	$	2,136	$	88,977

Our third quarter 2015 revenues increased $42,440 to $133,553 as compared to $91,113 during the third quarter 2014. Our third quarter 2015 cost of revenues increased $66,925 to $69,061as compared to $2,136 during the third quarter 2014 and our third quarter 2015 gross profits decreased $24,485 to $64,492 as compared to $88,977 during the third quarter 2014. These quarter-over-quarter changes in revenues, cost of revenues and gross profits mainly resulted from changes in the mix of products and services provided.

Our non-cannabis product revenues consist of sales of proprietary products used in the manufacture of our Prana medicinals products. During the third quarter of 2014 we had one customer purchasing our non-cannabis products on a regular basis as compared to no customers purchasing these products during the third quarter of 2015. We expect sales of our non-cannabis products to increase as we increase brand awareness and sales by third parties of our Prana medicinals products.

During the third quarter of 2015 and 2014, our license fees include the recognition of $45,000 and $75,000, respectively, of deferred revenue relating to our WeedMD RX Inc. (“WMD”) business arrangement. While we have not yet incurred any significant direct costs associated with this arrangement, we may incur costs in the future as WMD pursues its business goals. Our consulting fees and related reimbursable expenses were generated from two customers during the third quarter 2015 as compared to no fees from this category during the third quarter of 2014.

Sales and Marketing Expenses

Sales and marketing expenses were $400 and $20,205 for the three months ended September 30, 2015 and 2014, respectively. The decrease in sales and marking expenses was due to our focus on serving existing customers in the third quarter of 2015 as compared to our sales and marketing efforts applicable to new products and services in the third quarter of 2014. Our sales and marketing expenses were mainly comprised of third party consulting fees during the three months ended September 30, 2014.

Research and Development Expenses

Research and development expenses (“R&D”) were $0 and $94,751 for the three months ended September 30, 2015 and 2014, respectively. The decrease in R&D was due to our focus on sales of existing products and services in the third quarter of 2015 as compared to our R&D efforts applicable to new products and services during the third quarter of 2014. Our R&D expenses during the three months ended September 30, 2014, were mainly comprised of R&D consulting fees, materials and supplies.

General and Administrative Expenses

General and administrative expenses (“G&A”) were $361,794 and $522,421 for the three months ended September 30, 2015 and 2014, respectively. The $160,625 decrease in general and administrative expenses were mainly due to a one-time business development expense of $175,000 incurred in the third quarter of 2014 related to our equity investment in CRD.

G&A expenses consist of:


	Three Months Ended September 30,
	2015		2014		Change
Personnel related expenses	$	208,886	$	172,303	$	36,583
Professional fees		129,975		145,934		(15,959	)
Business development expense		—		175,000		(175,000	)
Travel and office related expanses		22,933		29,184		(6,251	)
Total G&A expenses	$	361,794	$	522,421	$	(160,627	)

The $36,583 increase in personnel related costs were comprised of non-cash share-based compensation expense accruals of $105,000 during the third quarter of 2015 as compared to $0 in the third quarter of 2014 offset by an allocation of $27,770 of personnel related costs to cost of revenues during the third quarter of 2015 as compared to $0 in the second quarter of 2014. The remaining $40,647 decrease in personnel related costs was due to a decrease in head count from five people in the third quarter of 2014 to three people in the third quarter of 2015.

The $15,959 decrease in professional fees were mainly comprised of a $65,921 decrease in legal and other professional fees from $121,134 in the third quarter of 2014 to $55,213 in the third quarter of 2015 which resulted from a decrease in activity related to our patent applications and equity method investments. This decrease was offset by a $49,962 increase in non-cash share-based compensation expense for services from $24,800 during the third quarter 2014 to $74,762 during the third quarter 2015.

The $6,251decrease in travel and office related expenses during the third quarter of 2015 as compared to the third quarter of 2014 were a result of cash conservation efforts while we focus on current operations.

Other Nonoperating (Income) Expense

Our other nonoperating (income) expense, net, decreased $137,885 to $20,353 during the three months ended September 30, 2015, as compared to $158,238 during the three months ended September 30, 2014. During the third quarter of 2015 our interest expense decreased $47,135 from $67,488 during the third quarter 2014 to $20,353 during the same period in 2015. In addition, during the third quarter of 2014 we incurred debt discount amortization of $89,152 and losses related to our derivative liability of $14,752; these amounts were offset by interest income of $13,154.

Nine Months Ended September 30, 2015 Compared to the Nine Months Ended September 30, 2014

Revenues, Cost of Revenues and Gross Profits

Components of revenues, cost of revenues and gross profit consist of:


	Nine Months Ended September 30, 2015
	Revenues		Cost of Revenues		Gross Profits
Non-cannabis products	$	204,425	$	17,374	$	187,051
License fees		167,441		3,000		164,441
Consulting fees		115,175		107,003		8,172
Reimbursable expenses		48,702		48,702		—
Total	$	535,743	$	176,079	$	359,664


	Nine Months Ended September 30, 2014
	Revenues		Cost of Revenues		Gross Profits
Non-cannabis products	$	9,212	$	2,136	$	7,076
License fees		81,901		—		81,901
Consulting fees		—		—		—
Reimbursable expenses		—		—		—
Total	$	91,113	$	2,136	$	88,977

Our first nine months of 2015 revenues increased $444,630 to $535,743 as compared to $91,113 during the first nine months of 2014. Our first nine months of 2015 cost of revenues increased $173,943 to $176,079 as compared to $2,136 during the first nine months of 2014 and our first nine months of 2015 gross profits increased $270,687 to $359,664 as compared to $88,977 during the first nine months of 2014. These increases in revenues, cost of revenues and gross profits reflect the fact that our first sales did not occur until the third quarter of 2014.

Our non-cannabis product revenues consist of sales of proprietary products used in the manufacture of our Prana medicinals products. During the first nine months of 2014 we had one customer purchasing our non-cannabis products on a regular basis as compared to two customers purchasing these products during the first nine months of 2015. We expect sales of our non-cannabis products to increase as we increase brand awareness and as sales by third parties of our Prana medicinals products increase.

During the first nine months of 2015 and 2014, our license fees include the recognition of $135,000 and $75,000, respectively, of deferred revenue relating to our WeedMD RX Inc. (“WMD”) business arrangement. While we have not yet incurred any significant costs associated with this arrangement, we may incur costs in the future as WMD pursues its business goals. Our consulting fees and related reimbursable expenses were generated from three customers during the first nine months of 2015 as compared to no fees from this category during the first nine months of 2014.

Sales and Marketing Expenses

Sales and marketing expenses were $2,100 and $94,363 for the nine months ended September 30, 2015 and 2014, respectively. The decrease in sales and marking expenses was due to our focus on serving existing customers in the first nine months of 2015 as compared to our sales and marketing efforts applicable to new products and services in the first nine months of 2014. Our sales and marketing expenses were mainly comprised of third party consulting fees during the nine months ended September 30, 2014.

Research and Development Expenses

Research and development expenses (“R&D”) were $329 and $170,805 for the nine months ended September 30, 2015 and 2014, respectively. The decrease in R&D expenses was due to our focus on sales of existing products and services in the first nine months of 2015 as compared to our R&D efforts applicable to new products and services during the first nine months of 2014. Our R&D expenses during the nine months ended September 30, 2014, were mainly comprised of R&D consulting fees, materials and supplies.

General and Administrative Expenses

General and administrative expenses (“G&A”) were $1,412,243 and $946,562 for the nine months ended September 30, 2015 and 2014, respectively. The $465,681 increase in general and administrative expenses were mainly due to a $614,309 increase in share-based compensation expense offset by a one-time business development expense of $175,000 as more fully described below.

G&A expenses consist of:


	Nine Months Ended September 30,
	2015		2014		Change
Personnel related expenses	$	690,820	$	381,373	$	309,447
Professional fees		643,300		285,482		357,818
Business development expense		—		175,000		(175,000	)
Travel and office related expanses		78,123		104,707		(26,584	)
Total G&A expenses	$	1,412,243	$	946,562	$	465,681

The $309,447 increase in personnel related costs were comprised of non-cash share-based compensation expense accruals of $315,000 during the first nine months of 2015 as compared to $0 in the first nine months of 2014 offset by an allocation of $107,003 of personnel related costs to cost of revenues during the first nine months of 2015 as compared to $0 in the first nine months of 2014. The remaining $101,450 increase in personnel related costs was due to the fact that we were just starting our operations in 2014.

The $357,818 increase in professional fees were mainly comprised of an increase of $299,309 in non-cash share-based compensation expense for services from $24,800 during the first three quarters of 2014 to $324,109 during the same period in 2015 and a $58,509 net increase in cash-based professional fees from $260,682 during the first nine months of 2014 to $319,191 during the first nine months of 2015. These increases were a result of an increase in corporate activity during our second year of operations.

The $26,584 decrease in travel and office related expenses during the first nine months of 2015 as compared to the first nine months of 2014 were a result of cash conservation efforts while we focus on current operations.

Other Nonoperating (Income) Expense

Our other nonoperating (income) expense, net, was $919,898 during the nine months ended September 30, 2015, as compared to $158,213 during the nine months ended September 30, 2014. This $761,685 increase was mainly comprised of a one-time $768,602 loss on repurchase of warrants from Typenex during the first nine months of 2015.

In addition, during the first nine months of 2015 our interest expense decreased $7,092 from $67,488 during the first nine months of 2014 to $60,396 during the same period in 2015. During the first nine months of 2015 we incurred a one-time net loss of $90,900 on our non-controlling interest in Lone Mountain Partners and this increase in non-operating expense was offset by the absence of debt discount amortization of $89,152, losses related to our derivative liability of $14,752 and increased by the absence of interest income of $13,179 recorded during the first nine months of 2014.

Discontinued Operations

On March 31, 2014 we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.

The following chart details our loss from discontinued operations for the nine and nine months ended September 30, 2015 and 2014:


	Nine Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014

Revenues	$	—	$	—	$	—	$	20,684

Operating expenses:
Selling, general and administrative		—		—		—		63,872
Loss on disposal of assets		—		—		—		15,704
Total operating expenses		—		—		—		79,576

Loss from discontinued operations, before income taxes		—		—		—		(58,892	)
Provision for income taxes		—		—		—		—

Loss from discontinued operations, net of income taxes	$	—	$	—	$	—	$	(58,892	)

Liquidity and Capital Resources

Our condensed consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2015, we incurred losses of $1,974,906 and used $304,297 of cash in our operating activities. As of September 30, 2015, we had a working capital deficit of $1,845,419 and an accumulated deficit of $4,599,873. Our ability to continue as a going concern depends on our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities when they come due. There is no assurance that these events will be satisfactorily completed.

Net cash used in operating activities for the nine months ending September 30, 2015 and 2014, was $304,297 and $1,093,057, respectively. This $788,760 decrease was primarily due to positive impacts to our operating cash flows resulting from a $270,667 increase in gross profits and decreases in marketing and R&D expenses of $92,263 and $170,476, respectively, during the nine months ending September 30, 2015 as compared to the same period in 2014.

Net cash used in investing activities for the nine months ending September 30, 2015 and 2014, was $14,385 and $50,000, respectively. This decrease was due to $14,385 of payments applicable to our trademarks and provisional patents during the current period compared to our $50,000 cash equity investment in Lone Mountain during the nine months ended September 30, 2014.

Net cash provided by financing activities for the nine months ending September 30, 2015 and 2014, was $0 and $1,300,000, respectively. The decrease was due to $900,000 from the sale of our common stock and warrants and $400,000 of proceeds from borrowings during the nine months ended September 30, 2014, compared to no cash financing activities during the current period.

Critical Accounting Policies

The preparation of condensed consolidated financial statements and related disclosures in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified in Note 2 - "Summary of Significant Accounting Policies" to the condensed consolidated financial statements contained in this Quarterly Report certain critical accounting policies that affect the more significant judgments and estimates used in the preparation of our condensed financial statements.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Contractual Obligations

Not applicable for smaller reporting companies.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable for smaller reporting companies.

ITEM 4.

CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures: We maintain a system of controls and procedures designed to ensure that information required to be disclosed in reports filed or submitted under the Securities Exchange Act of 1934, as amended ("1934 Act"), is recorded, processed, summarized and reported, within time periods specified in the SEC's rules and forms and to ensure that information required to be disclosed by us in the reports that we file or submit under the 1934 Act, is accumulated and communicated to our management, including our Principal Executive and Financial Officer, as appropriate to allow timely decisions regarding required disclosure. As of September 30, 2015, our Principal Executive and Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, the Principal Executive and Financial Officer concluded that our disclosure controls and procedures were not effective.

(b) Changes in Internal Control over Financial Reporting: There were no changes in our internal control over financial reporting during the first nine months quarter ending September 30, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

We are not a party to any material legal proceedings.

ITEM 1A.

RISK FACTORS.

Not applicable for smaller reporting companies.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On August 15, 2014, we issued an aggregate of 40,000 shares of our common stock to six individuals valued at a total of $88,000 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The shares were issued in settlement of a dispute over the terms of an outstanding warrant. The issuance of these shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

On February 10, 2015, we issued 621,000 shares of our common stock to a third party valued at a total of $987,390 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The shares were issued in settlement of a dispute over the terms of an outstanding warrant. The issuance of these shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

On March 2, 2015, we issued 30,000 shares of our common stock to a consultant for consulting services valued at a total of $42,600 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuances of these shares were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

On April 23, 2015, we issued a total of 186,500 shares of our common stock to two consultants for prepaid consulting services valued at a total of $147,335 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuances of these shares were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

On August 17, 2015, we issued 50,000 shares of our common stock to a consultant for consulting services valued at a total of $19,000 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuances of these shares were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

On August 24, 2015, we issued 11,000 shares of our common stock to two consultants for consulting services valued at a total of $5,280 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuances of these shares were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

On October 19, 2015, we issued 30,000 shares of our common stock to a third party for intellectual property licensing fees valued at a total of $12,000 based on the closing price of our common stock on the day before the issuance of the shares was approved by the Board of Directors. The issuances of these shares were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES AND USE OF PROCEEDS.

We are currently in default under the terms of our $600,000 unsecured promissory note due December 17, 2015, plus accrued interest of $56,416 as of September 30, 2015, as a result of our borrowings on October 6 and October 12, 2015, in the amounts of $59,000 and $102,000, respectively. Under the terms of the $600,000 promissory note we agreed to not incur any indebtedness until the promissory note and accrued interest were paid in full.

ITEM 4.

MINES SAFETY DISCLOSURES.

Not applicable to our Company.

ITEM 5.

OTHER INFORMATION.

None

ITEM 6.

EXHIBITS.


Exhibits

31		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Security Exchange Act Rule 13a-14 and 15d-14.

32		Certification of the Company’s Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		XBRL Exhibits

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	UNITED CANNABIS CORPORATION

Date: November 16, 2015	By:	/s/ Earnest Blackmon
		Earnest Blackmon
		Chief Executive Officer and Principal Financial Officer

Attached files

United Cannabis Corp Reports

Also read